The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed. ...

(Reuters) -Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, which has been called into question by Novo Nordisk's higher $8.5 billion offer. Metsera has declared Novo's offer superior, and given Pfizer until Tuesday to raise its bid. The U.S. Federal Trade Commission granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews. The waiting period was originally set to e ...

TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows: UBS Global Healthcare ConferenceMonday, November 10, 2025, at 8:45 A.M. Eastern Time (ET) Jefferies London Healthcare ConferenceTuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET) To access a live webcast of the presentation, visit Teva’s ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin†or the "Company†), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, is pleased to announce that it has closed its previously announced registered direct offering of 22,277,750 common shares in the capital of the Company (a "Common Share†) and, in lieu of Common Shares to certa. ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin†or the "Company†), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, is pleased to announce that it has closed its previously announced registered direct offering of 22,277,750 common shares in the capital of the Company (a "Common Share†) and, in lieu of Common Shares to certa. ...

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between January 16, 2025 and September 12, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-subm ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - AbbVie Inc. raised its full-year profit forecast due to strong demand for its psoriasis treatment Skyrizi, leading to third-quarter sales that exceeded expectations, although shares fell over 4% in intra-day trading [1] Financial Performance - For the quarter ending in September, AbbVie reported a net revenue increase of 9.1% year-over-year, reaching $15.78 billion, driven by strong sales of Skyrizi and Rinvoq [2] - Adjusted earnings per share for the quarter were $1.86, a decrease from $4.86 a year earlier, but above Bloomberg's consensus estimate of $1.77 [2] Product Performance - The growth in immunology products helped mitigate the decline in Humira, which has faced significant competition from lower-cost biosimilars since 2023 [3] - Rinvoq generated $5.97 billion in revenue in 2024, representing approximately half of AbbVie's total sales, with expectations that Rinvoq and Skyrizi will together contribute about $31 billion in revenue by 2027 [3]

Key Takeaways Agios reported a Q3 loss of $1.78 per share, beating expectations of a loss of $1.93.AGIO's total revenues climbed 44% year over year to $12.9 million, fueled by Pyrukynd sales.The FDA decision on Pyrukynd's thalassemia indication is due on Dec. 7, as the EMA gives a positive opinion.Agios Pharmaceuticals (AGIO) incurred a loss of $1.78 per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.93. In the year-ago quarter, the company had reported earnin ...

Key Takeaways Apellis posted Q3 EPS of $1.67, beating estimates, versus a loss of 46 cents a year ago.Revenues more than doubled to $458.6M, lifted by a $275M upfront payment from Sobi.Syfovre sales fell 1% year over year, missing expectations and weighing on investor sentiment.Apellis Pharmaceuticals (APLS) reported third-quarter 2025 earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.03 per share. The company had incurred a loss of 46 cents in the year-ago quarter.Total revenues in th ...